1. HerseySJ, SachsG. Gastric acid secretion. Physiol Rev1995;75:155.

2. ZengN, AthmannC, KangT, et al.PACAP type I receptor activation regulates ECL cells and gastric acid secretion. J Clin Invest1999;104:1383. CrossRef

3. MiampambaM, GermanoPM, ArliS, et al.Expression of pituitary adenylate cyclase‐activating polypeptide and PACAP type 1 receptor in the rat gastric and colonic myenteric neurons. Regul Pept2002;105:145. CrossRef

4. GregoryRA, TracyHJ. The constitution and properties of two gastrins extracted from hog antral mucosa. Gut1964;5:103. CrossRef

5. McGuiganJE. Antibodies to the carboxyl‐terminal tetrapeptide of gastrin. Gastroenterology1967;53:697.

6. WankSA, PisegnaJR, de WeerthA. Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression. Proc Natl Acad Sci U S A1992;89:8691. CrossRef

7. PisegnaJR, de WeerthA, HuppiK, et al.Molecular cloning of the human brain and gastric cholecystokinin receptor: structure, functional expression and chromosomal localization. Biochem Biophys Res Commun1992;189:296. CrossRef

8. KopinAS, LeeYM, McBrideEW, et al.Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci U S A1992;89:3605. CrossRef

9. HartyRF, MaicoDG, McGuiganJE. Antral release of gastrin and somatostatin in duodenal ulcer and control subjects. Gut1986;27:652. CrossRef

10. CardWI, MarksIN. The relationship between the acid output of the stomach following “maximal” histamine stimulation and the parietal cell mass. Clin Sci1960;19:147.

11. MakhloufGM, McmanusJP, CardWI. The action of gastrin ii on gastric‐acid secretion in man. comparison of the “maximal” secretory response to gastrin ii and histamine. Lancet1964;2:485. CrossRef

12. IsenbergJI, GrossmanMI, MaxwellV, et al.Increased sensitivity to stimulation of acid secretion by pentagastrin in duodenal ulcer. J Clin Invest1975;55:330. CrossRef

13. PisegnaJR, MartinP, McKeandW, et al.Inhibition of pentagastrin‐induced gastric acid secretion by intravenous pantoprazole: a dose‐response study. Am J Gastroenterol1999;94:2874. CrossRef

14. McGuiganJE, TrudeauWL. Immunochemical measurement of elevated levels of gastrin in the serum of patients with pancreatic tumors of the Zollinger‐Ellison variety. N Engl J Med1968;278:1308. CrossRef

15. TrudeauWL, McGuiganJE. Effects of calcium on serum gastrin levels in the zollinger‐Ellison syndrome. N Engl J Med1969;281:862. CrossRef

16. GoebelSU, PeghiniPL, GoldsmithPK, et al.Expression of the calcium‐sensing receptor in gastrinomas. J Clin Endocrinol Metab2000;85:4131. CrossRef

17. RomanusME, NealJA, DilleyWG, et al.Comparison of four provocative tests for the diagnosis of gastrinoma. Ann Surg1983;197:608. CrossRef

18. VezzadiniC, PoggioliR, CasoniI, et al.Use of calcium provocative test in the diagnosis of gastroenteropancreatic endocrine tumors. Panminerva Med1996;38:255.

19. FengJ, PetersenCD, CoyDH, et al.Calcium‐sensing receptor is a physiologic multimodal chemosensor regulating gastric G‐cell growth and gastrin secretion. Proc Natl Acad Sci U S A2010;107:17791. CrossRef

20. MetzDC. Diagnosis of the Zollinger–Ellison syndrome. Clin Gastroenterol Hepatol2012;10:126. CrossRef

21. RehfeldJF, GingrasM‐H, BardramL, et al.The Zollinger‐Ellison syndrome and mismeasurement of gastrin. Gastroenterology2011;140:1444. CrossRef

22. FruchtH, HowardJM, SlaffJI, et al.Secretin and calcium provocative tests in the Zollinger‐Ellison syndrome. A prospective study. Ann Intern Med1989;111:713. CrossRef

23. MetzDC, PisegnaJR, FishbeynVA, et al.Currently used doses of omeprazole in Zollinger‐Ellison syndrome are too high. Gastroenterology1992;103:1498.

24. FishbeynVA, NortonJA, BenyaRV, et al.Assessment and prediction of long‐term cure in patients with the Zollinger‐Ellison syndrome: the best approach. Ann Intern Med1993;119:199. CrossRef

25. LichtenbergerLM, DialEJ, RomeroJJ, et al.Role of luminal ammonia in the development of gastropathy and hypergastrinemia in the rat. Gastroenterology1995;108:320. CrossRef

26. KwanCP, TytgatGN. Antral G‐cell hyperplasia: a vanishing disease?Eur J Gastroenterol Hepatol1995;7:1099. CrossRef

27. GibrilF, LindemanRJ, Abou‐SaifA, et al.Retained gastric antrum syndrome: a forgotten, treatable cause of refractory peptic ulcer disease. Dig Dis Sci2001;46:610. CrossRef

28. LeeCH, P'engFK, YehPH. Sodium pertechnetate Tc 99m antral scan in the diagnosis of retained gastric antrum. Arch Surg1984;119:309. CrossRef

29. BorgJ, MelanderO, JohanssonL, et al.Gastroparesis is associated with oxytocin deficiency, oesophageal dysmotility with hyper‐CCKemia, and autonomic neuropathy with hypergastrinemia. BMC Gastroenterol2009;9:17. CrossRef

30. MigdalisL, ThomaidesT, ChairopoulosC, et al.Changes of gastric emptying rate and gastrin levels are early indicators of autonomic neuropathy in type II diabetic patients. Clin Auton Res2001;11:259. CrossRef

31. KormanMG, HanskyJ, StricklandRG. Progressive increase in the functional G cell mass with age in atrophic gastritis. Gut1973;14:549. CrossRef

32. StricklandRG, BhathalPS, KormanMG, et al.Serum gastrin and the antral mucosa in atrophic gastritis. Br Med J1971;4:451. CrossRef

33. KaessH, CheliR, De BenedettiF, et al.Morphology of the gastric mucosa, gastric secretion and serum gastrin concentration following a test meal. Digestion1978;17:18. CrossRef

34. MooreAR, BoyceM, SteeleIA, et al.Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS ONE2013;8:e76462. CrossRef

35. SullivanSN, TustanoffE, SlaughterDN, et al.Hypergastrinemia and gastric acid hypersecretion in uremia. Clin Nephrol1976;5:25.

36. LichtenbergerLM, GardnerJW, BarretoJC, et al.Accumulation of aliphatic amines in gastric juice of acute renal failure patients. Possible cause of hypergastrinemia associated with uremia. Dig Dis Sci1993;38:1885. CrossRef

37. QuinteroE, OhningGV, Del RiveroM, et al.Gastrin mediates the increase in gastric cell growth in uremic rats. Am J Physiol1995;268:G586.

38. WankSA, PisegnaJR, de WeerthA. Cholecystokinin receptor family. Molecular cloning, structure, and functional expression in rat, guinea pig, and human. Ann N Y Acad Sci1994;713:49. CrossRef

39. TrejtnarF, LaznicekM, LaznickovaA, et al.Biodistribution and elimination characteristics of two 111In‐labeled CCK‐2/gastrin receptor‐specific peptides in rats. Anticancer Res2007;27:907.

40. ChenY, AsicoLD, ZhengS, et al.Gastrin and d1 dopamine receptor interact to induce natriuresis and diuresis. Hypertension2013;62:927. CrossRef

41. OdashimaM, OtakaM, JinM, et al.Rapid regression of multiple gastric carcinoid tumors with hypergastrinemia and atrophic gastritis after renal transplantation. Dig Dis Sci2008;53:865. CrossRef

42. FrestonJW. Long‐term acid control and proton pump inhibitors: interactions and safety issues in perspective. Am J Gastroenterol1997;92(4 Suppl):51S; discussion 55S.

43. KarnesWEJr, WalshJH. The gastrin hypothesis. Implications for antisecretory drug selection. J Clin Gastroenterol1990;12(Suppl 2):S7. CrossRef

44. WaldumHL, QvigstadG, FossmarkR, et al.Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scand J Gastroenterol2010;45:389. CrossRef

45. ShiratoriK, WatanabeS, TakeuchiT. Serum gastrin levels in response to exogenous secretin in patients with duodenal ulcer–false positive response occurring in case of endoscopically active ulcer. Gastroenterol Jpn1982;17:80.

46. LongSH, BernaMJ, ThillM, et al.Secretin‐receptor and secretin‐receptor‐variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results. J Clin Endocrinol Metab2007;92:4394. CrossRef

47. MetzDC, BuchananM, PurichE, et al.A randomized controlled crossover study comparing synthetic porcine and human secretins with biologically derived porcine secretin to diagnose Zollinger‐Ellison Syndrome. Aliment Pharmacol Ther2001;15:669. CrossRef

48. ShibataC, FunayamaY, FukushimaK, et al.The glucagon provocative test for the diagnosis and treatment of Zollinger‐Ellison syndrome. J Gastrointest Surg2008;12:344. CrossRef

49. SeastoneCV, HerriottRM. Immunological studies on pepsin and pepsinogen. J Gen Physiol1937;20:797. CrossRef

50. SutliffVE, RaufmanJP, JensenRT, et al.Actions of vasoactive intestinal peptide and secretin on chief cells prepared from guinea pig stomach. Am J Physiol1986;251:G96.

51. FelleyCP, QianJM, ManteyS, et al.Chief cells possess a receptor with high affinity for PACAP and VIP that stimulates pepsinogen release. Am J Physiol1992;263:G901.

52. WaldumHL, BurholPG. The effect of secretin on serum group I pepsinogens (PG I) in man. Scand J Gastroenterol1980;15:273. CrossRef

53. MikiK, MoritaM, SasajimaM, et al.Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol2003;98:735. CrossRef

54. WalshJH. Functional and provocative tests for gastroduodenal disorders. J Clin Gastroenterol1981;3(Suppl 2):73.

55. MaedaK, ChungY, OnodaN, et al.Prognostic value of serum pepsinogen levels in patients with gastric‐carcinoma. Int J Oncol1993;3:437.

56. GisbertJP, BoixedaD, VilaT, et al.Verification of decreased basal and stimulated serum pepsinogen‐I levels is a useful non‐invasive method for determining the success of eradication therapy for Helicobacter pylori. Scand J Gastroenterol1996;31:103. CrossRef

57. MikiK, UritaY. Using serum pepsinogens wisely in a clinical practice. J Dig Dis2007;8:8. CrossRef

58. BodgerK, WyattJI, HeatleyRV. Serologic screening before endoscopy: the value of Helicobacter pylori serology, serum recognition of the CagA and VacA proteins, and serum pepsinogen I. Scand J Gastroenterol1999;34:856. CrossRef

59. HumbertP, López de SoriaP, Fernández‐BañaresF, et al.Magnesium hydrogen breath test using end expiratory sampling to assess achlorhydria in pernicious anaemia patients. Gut1994;35:1205. CrossRef

60. CloughMRI, AxonATR. The Calcium Carbonate Breath Test, a noninvasive test of stimulated gastric acid secretion: preliminary communication. Eur J Gastroenterol Hepatol2009;21:266. CrossRef

61. AndresMRJr, BinghamJR. Tubeless gastric analysis with a radiotelemetering pill (Heidelberg capsule). Can Med Assoc J1970;102:1087.

62. SippyHI, FitzsimonsEJ. Measurement of free acid in gastric juice by means of indicator paper. J Am Med Assoc1959;170:1157. CrossRef

63. AubreyDA. The effects on human gastric secretion of prolonged continuous intravenous infusions of maximal and supramaximal doses of histamine acid phosphate and pentagastrin. Gut1970;11:392. CrossRef

64. FordtranJS, WalshJH. Gastric acid secretion rate and buffer content of the stomach after eating. Results in normal subjects and in patients with duodenal ulcer. J Clin Invest1973;52:645. CrossRef

65. LewinMR, StaggBH, ClarkCG. Gastric acid secretion and diagnosis of Zollinger‐Ellison syndrome. Br Med J1973;2:139. CrossRef

66. MalageladaJR, LongstrethGF, SummerskillWH, et al.Measurement of gastric functions during digestion of ordinary solid meals in man. Gastroenterology1976;70:203.

67. MaxwellV, EysseleinVE, KleibeukerJ, et al.Glucose perfusion intragastric titration. Dig Dis Sci1984;29:321. CrossRef

68. BeutlerSM, SamloffIM. Measurement of acid secretion by Tc‐scan. Gastroenterology1980;78:1657.

69. YamaguchiH, NakazawaS, SegawaK, et al.Precise gastric secretory studies using a new fiber‐gastroscope. Hepatogastroenterology1987;34:215.

70. OhDS, WangHS, OhningGV, et al.Validation of a new endoscopic technique to assess acid output in Zollinger‐Ellison syndrome. Clin Gastroenterol Hepatol2006;4:1467. CrossRef

71. WeinsteinDH, deRijkeS, ChowCC, et al.A new method for determining gastric acid output using a wireless pH‐sensing capsule. Aliment Pharmacol Ther2013;37:1198. CrossRef

72. MetzDC, StarrJA. A retrospective study of the usefulness of acid secretory testing. Aliment Pharmacol Ther2000;14:103. CrossRef

73. GhoshT, LewisDI, AxonATR, et al.Review article: methods of measuring gastric acid secretion. Aliment Pharmacol Ther2011;33:768. CrossRef

74. SchubertML. Gastric secretion. Curr Opin Gastroenterol2008;24:659. CrossRef

75. LawrieJH, ForrestAP. The measurement of gastric acid. Postgrad Med J1965;41:408. CrossRef

76. MeeroffJC. The nomenclature of gastric acid output. Dig Dis Sci1979;24:87. CrossRef

77. KayAW. Effect of large doses of histamine on gastric secretion of HCI; an augmented histamine test. Br Med J1953;2:77. CrossRef

78. JohnstonD, JepsonK. Use of pentagastrin in a test of gastric acid secretion. Lancet1967;2:585. CrossRef

79. KosterKH, RodbroP, PetersenHJ. Comparative effects of tetragastrin and histamine on acid and intransic factor secretion in man. Scand J Gastroenterol1968;3:23. CrossRef

80. McCollKE, el‐OmarE. Review article: gastrin releasing peptide and its value in assessing gastric secretory function. Aliment Pharmacol Ther1995;9:341. CrossRef

81. PrathaVS, HoganDL, LaneJR, et al.Inhibition of pentagastrin‐stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults. Dig Dis Sci2006;51:123. CrossRef

82. EisenbandRM, WengerJ. Endoscopic estimate of gastric acid secretion. J Clin Gastroenterol1981;3:287. CrossRef

83. IijimaK, OharaS, SekineH, et al.A new endoscopic method of gastric acid secretory testing. Am J Gastroenterol1998;93:2113. CrossRef

84. Van HerwaardenMA, SamsomM, SmoutAJ. 24‐h recording of intragastric pH: technical aspects and clinical relevance. Scand J Gastroenterol Suppl1999;230:9. CrossRef

85. FacklerWK, VaeziMF, RichterJE. Ambulatory gastric pH monitoring: proper probe placement and normal values. Aliment Pharmacol Ther2001;15:1155. CrossRef

86. GardnerJD, Rodriguez‐StanleyS, RobinsonM. Integrated acidity and the pathophysiology of gastroesophageal reflux disease. Am J Gastroenterol2001;96:1363. CrossRef

87. BanerjeeR, ReddyDN. Bravo capsule pH monitoring. Am J Gastroenterol2006;101:906; author reply 907. CrossRef

88. YamaguchiT, SezaA, OdakaT, et al.Placement of the Bravo wireless pH monitoring capsule onto the gastric wall under endoscopic guidance. Gastrointest Endosc2006;63:1046. CrossRef

89. ChangJH, ChoiMG, YimD‐S, et al.A novel placement method of the Bravo wireless pH monitoring capsule for measuring intragastric pH. Dig Dis Sci2009;54:578. CrossRef

90. PisegnaJR, NortonJA, SlimakGG, et al.Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger‐Ellison syndrome. Gastroenterology1992;102:767.

91. Domínguez MuñozJE. Diagnosis of chronic pancreatitis: Functional testing. Best Pract Res Clin Gastroenterol2010;24:233. CrossRef

92. RaufmanJP, MalhotraR, SinghL. PACAP‐38, a novel peptide from ovine hypothalamus, is a potent modulator of amylase release from dispersed acini from rat pancreas. Regul Pept1991;36:121. CrossRef

93. BoydEJ, WormsleyKG. Laboratory tests in the diagnosis of the chronic pancreatic diseases. Part 1. Secretagogues used in tests of pancreatic secretion. Int J Pancreatol1987;2:137.

94. BoydEJ, WormsleyKG. Laboratory tests in the diagnosis of the chronic pancreatic diseases. Part 2. Tests of pancreatic secretion. Int J Pancreatol1987;2:211.

95. WangY, PrpicV, GreenGM, et al.Luminal CCK‐releasing factor stimulates CCK release from human intestinal endocrine and STC‐1 cells. Am J Physiol Gastrointest Liver Physiol2002;282:G16.

96. ConwellDL, ZuccaroGJr, VargoJJ, et al.An endoscopic pancreatic function test with synthetic porcine secretin for the evaluation of chronic abdominal pain and suspected chronic pancreatitis. Gastrointest Endosc2003;57:37. CrossRef

97. ConwellDL, ZuccaroGJr, VargoJJ, et al.An endoscopic pancreatic function test with cholecystokinin‐octapeptide for the diagnosis of chronic pancreatitis. Clin Gastroenterol Hepatol2003;1:189. CrossRef

98. CzakóL. Diagnosis of early‐stage chronic pancreatitis by secretin‐enhanced magnetic resonance cholangiopancreatography. J Gastroenterol2007;42(Suppl 17):113. CrossRef

99. Bo‐LinnGW, FordtranJS. Fecal fat concentration in patients with steatorrhea. Gastroenterology1984;87:319.

100. RobertsIM, PoturichC, WaldA. Utility of fecal fat concentrations as screening test in pancreatic insufficiency. Dig Dis Sci1986;31:1021. CrossRef

101. MolinariI, SouareK, LamireauT, et al.Fecal chymotrypsin and elastase‐1 determination on one single stool collected at random: diagnostic value for exocrine pancreatic status. Clin Biochem2004;37:758. CrossRef

102. LöserC, MöllgaardA, FölschUR. Faecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test. Gut1996;39:580. CrossRef

103. Domínguez‐MuñozJE, HieronymusC, SauerbruchT, et al.Fecal elastase test: evaluation of a new noninvasive pancreatic function test. Am J Gastroenterol1995;90:1834.

104. VantrappenGR, RutgeertsPJ, GhoosYF, et al.Mixed triglyceride breath test: a noninvasive test of pancreatic lipase activity in the duodenum. Gastroenterology1989;96:1126.

105. O'ConnorDT, DeftosLJ. Secretion of chromogranin A by peptide‐producing endocrine neoplasms. N Engl J Med1986;314:1145. CrossRef

106. IppolitiAF, SturdevantRA, IsenbergJI, et al.Cimetidine versus intensive antacid therapy for duodenal ulcer: a multicenter trial. Gastroenterology1978;74:393.

107. JensenRT. Basis for failure of cimetidine in patients with Zollinger‐Ellison syndrome. Dig Dis Sci1984;29:363. CrossRef

108. JonesB, FishmanEK, BaylessTM, et al.Villous hypertrophy of the small bowel in a patient with glucagonoma. J Comput Assist Tomogr1983;7:334. CrossRef

109. StacpoolePW. The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev1981;2:347. CrossRef

110. StevensFM, FlanaganRW, O'GormanD, et al.Glucagonoma syndrome demonstrating giant duodenal villi. Gut1984;25:784. CrossRef

111. FriesenSR, HermreckAS, MantzFAJr. Glucagon, gastrin, and carcinoid tumors of the duodenum, pancreas, and stomach: polypeptide “apudomas” of the foregut. Am J Surg1974;127:90. CrossRef

112. MozellE, StenzelP, WolteringEA, et al.Functional endocrine tumors of the pancreas: clinical presentation, diagnosis, and treatment. Curr Probl Surg1990;27:301. CrossRef

113. GalbutDL, MarkowitzAM. Insulinoma: diagnosis, surgical management and long‐term follow‐up. Review of 41 cases. Am J Surg1980;139:682. CrossRef

114. GierckskyKE, HalseJ, MathisenW, et al.Endocrine tumors of the pancreas. Scand J Gastroenterol1980;15:129. CrossRef

115. GlickmanMH, HartMJ, WhiteTT. Insulinoma in Seattle: 39 cases in 30 years. Am J Surg1980;140:119. CrossRef

116. Le QuesneLP, NabarroJD, KurtzA, et al.The management of insulin tumours of the pancreas. Br J Surg1979;66:373. CrossRef

117. ServiceFJ, DaleAJ, ElvebackLR, et al.Insulinoma: clinical and diagnostic features of 60 consecutive cases. Mayo Clin Proc1976;51:417.

118. Van HeerdenJA, EdisAJ, ServiceFJ. The surgical aspects of insulinomas. Ann Surg1979;189:677. CrossRef

119. MerimeeTJ, TysonJE. Stabilization of plasma glucose during fasting; Normal variations in two separate studies. N Engl J Med1974;291:1275. CrossRef

120. MerimeeTJ, TysonJE. Hypoglycemia in man pathologic and physiologic variants. Diabetes1977;26:161. CrossRef

121. GutmanRA, LazarusNR, PenhosJC, et al.Circulating proinsulin‐like material in patients with functioning insulinomas. N Engl J Med1971;284:1003. CrossRef

122. ShermanBM, PekS, FajansSS, et al.Plasma proinsulin in patients with functioning pancreatic islet cell tumors. J Clin Endocrinol Metab1972;35:271. CrossRef

123. GrunbergerG, WeinerJL, SilvermanR, et al.Factitious hypoglycemia due to surreptitious administration of insulin. Diagnosis, treatment, and long‐term follow‐up. Ann Intern Med1988;108:252. CrossRef

124. GrantCS. Gastrointestinal endocrine tumours. Insulinoma. Baillieres Clin Gastroenterol1996;10:645. CrossRef

125. O'DorisioTM, MekhjianHS, GaginellaTS. Medical therapy of VIPomas. Endocrinol Metab Clin North Am1989;18:545.

126. AlbertiKG, OxburyJM, HigginsG. Factitious hypoglycaemia: chlorpropamide self‐administration by a non‐diabetic. Br Med J1972;1:87. CrossRef

127. CoopermanAM, DesantisD, WinkelmanE, et al.Watery diarrhea syndrome. Two unusual cases and further evidence that VIP is a humoral mediator. Ann Surg1978;187:325. CrossRef

128. Rønnov‐JensenD, GetherU, FahrenkrugJ. PreproVIP‐derived peptides in tissue and plasma from patients with VIP‐producing tumours. Eur J Clin Invest1991;21:154. CrossRef

129. LowrySF, BurtME, BrennanMF. Glucose turnover and gluconeogenesis in a patient with somatostatinoma. Surgery1981;89:309.

130. KonomiK, ChijiiwaK, KatsutaT, et al.Pancreatic somatostatinoma: a case report and review of the literature. J Surg Oncol1990;43:259. CrossRef

131. VinikAI, StrodelWE, EckhauserFE, et al.Somatostatinomas, PPomas, neurotensinomas. Semin Oncol1987;14:263.

132. GalmicheJP, ChayvialleJA, DuboisPM, et al.Calcitonin‐producing pancreatic somatostatinoma. Gastroenterology1980;78:1577.

133. BodenG, BaileCA, McLaughlinCL, et al.Effects of starvation and obesity on somatostatin, insulin, and glucagon release from an isolated perfused organ system. Am J Physiol1981;241:E215.

134. FruchtH, MatonPN, JensenRT. Use of omeprazole in patients with Zollinger‐Ellison syndrome. Dig Dis Sci1991;36:394. CrossRef

135. LonovicsJ, DevittP, WatsonLC, et al.Pancreatic polypeptide. A review. Arch Surg1981;116:1256. CrossRef

136. KentRB3rd, van HeerdenJA, WeilandLH. Nonfunctioning islet cell tumors. Ann Surg1981;193:185. CrossRef

137. EckhauserFE, CheungPS, VinikAI, et al.Nonfunctioning malignant neuroendocrine tumors of the pancreas. Surgery1986;100:978.

138. ErikssonB, ObergK, SkogseidB. Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patients. Acta Oncol1989;28:373. CrossRef

139. BloomSR, AdrianTE, BryantMG, et al.Pancreatic polypeptide: a marker for Zollinger‐Ellison syndrome?Lancet1978;1:1155. CrossRef

140. VuJP, WangHS, GermanoPM, et al.Ghrelin in neuroendocrine tumors. Peptides2011;32:2340. CrossRef

141. WangHS, OhDS, OhningGV, et al.Elevated serum ghrelin exerts an orexigenic effect that may maintain body mass index in patients with metastatic neuroendocrine tumors. J Mol Neurosci2007;33:225. CrossRef

142. DayalY, LinHD, TallbergK, et al.Immunocytochemical demonstration of growth hormone‐releasing factor in gastrointestinal and pancreatic endocrine tumors. Am J Clin Pathol1986;85:13.

143. BergerG, TrouillasJ, BlochB, et al.Multihormonal carcinoid tumor of the pancreas. Secreting growth hormone‐releasing factor as a cause of acromegaly. Cancer1984;54:2097. CrossRef

144. MatonPN, GardnerJD, JensenRT. Cushing's syndrome in patients with the Zollinger‐Ellison syndrome. N Engl J Med1986;315:1. CrossRef

145. ÖzkanZG, KuyumcuS, BalköseD, et al.The value of somatostatin receptor imaging with In‐111 Octreotide and/or Ga‐68 DOTATATE in localizing Ectopic ACTH producing tumors. Mol Imaging Radionucl Ther2013;22:49. CrossRef